Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...6970717273747576777879...123124»
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Single-center real-world treatment and outcomes in patients with hepatocellular carcinoma receiving immunotherapy. (In-Person Only | Level 1, West Hall; Poster Board - A10) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_258;    
    Survival outcomes in this cohort are impacted by the inclusion of patients with more compromised liver function and less restrictive pt selection compared to clinical trials. Usage of TKIs post ICI is feasible with suggestion of clinical activity but this is an area in need of prospective studies.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. (In-Person Only | Level 1, West Hall; Poster Board - M4) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_179;    
    P3
    For part 1, safety run-in, ≥12 patients will be treated for induction with IV pembrolizumab 400 mg Q6W (×2) + oral lenvatinib 8 mg QD + investigator’s choice of chemotherapy (CAPOX Q3W ×4 [oral capecitabine 1000 mg/m2 BID for 14 days + IV oxaliplatin 130 mg/m2] or mFOLFOX6 Q2W ×6 [bolus IV 5-FU 400 mg/m2 + continuous IV 5-FU 2400 mg/m2 + IV leucovorin 400 mg/m2 or levoleucovorin 200 mg/m2 + IV oxaliplatin 85 mg/m2 ]) and for consolidation with pembrolizumab 400 mg Q6W for ≤16 doses + lenvatinib 20 mg QD; dose-limiting toxicities will be evaluated for 21 days...In part 2, dual primary end points are OS and PFS (per RECIST v1.1 assessed by BICR) in patients with PD-L1 combined positive score (CPS) ≥1 and in all patients; secondary end points include objective response rate and duration of response (per RECIST v1.1 assessed by BICR) in patients with PD-L1 CPS ≥1 and in all patients, and safety and tolerability in all patients. Recruitment is ongoing.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma. (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_178;    
    P3
    Approximately 850 patients will be randomly assigned 1:1 to induction with pembrolizumab plus lenvatinib plus chemotherapy (FP or mFOLFOX6 [Q2W for 6 cycles {IV oxaliplatin 85 mg/m2 plus bolus IV 5-FU 400 mg/m2 plus continuous IV 5-FU 2400 mg/m2 plus IV leucovorin 400 mg/m2 or IV levoleucovorin 200 mg/m2}]) followed by consolidation with pembrolizumab plus lenvatinib (arm 1) or pembrolizumab plus chemotherapy (FP or mFOLFOX6; arm 2)...In part 1, the primary end point is safety and tolerability. In part 2, the dual primary end points are overall survival and progression-free survival (per RECIST v1.1 assessed by blinded independent central review [BICR]); secondary end points include objective response rate and duration of response (per RECIST v1.1 assessed by BICR) and safety and tolerability.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Targeting Key Transcription Factors in Hepatocellular Carcinoma. (Pubmed Central) -  Dec 2, 2021   
    Dysregulation of transcription factors, the central modulators of normal and transformed tumorous cellular processes such as STAT-1, STAT-3, NF-κB, Ap1, and HIF-1α are known to be activated in HCC invasion, progression, and metastasis are highlighted in this review. The recently approved drugs, such as sorafenib regorafenib, lenvatinib, and cabozantinib, are tyrosine kinase inhibitors (TKIs), which completely reduce HCC progression by targeting transcription factors are discussed.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Lenvatinib in severe hypoglycemia associated with hepatocelular carcinoma. (Pubmed Central) -  Dec 1, 2021   
    After ruling out different possibilities, the suspicion of hypoglycemia due to a non-islet cell tumor was finally confirmed. Given the impossibility of a curative treatment due to a reduced functional reserve, Sorafenib was changed to Lenvatinib, thereby improving glycemic control.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Hepatocellular carcinoma. (Pubmed Central) -  Nov 29, 2021   
    New trials are exploring combination therapies, including checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies, or even combinations of two immunotherapy regimens. The outcomes of these trials are expected to change the landscape of HCC management at all evolutionary stages.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Systemic therapy for hepatocellular carcinoma: current status and future perspectives. (Pubmed Central) -  Nov 29, 2021   
    Regorafenib, cabozantinib and ramucirumab have been demonstrated to show survival benefits as second-line treatment agents for progressive disease after first-line sorafenib treatment...A promising treatment for Child-Pugh class B hepatocellular carcinoma patients is also an urgent medical need that has not yet been met. Although there are some difficulties in establishing the needed evidence, well-designed clinical trials are warranted.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Current status and future perspectives of immunotherapy against urothelial and kidney cancer. (Pubmed Central) -  Nov 29, 2021   
    So far, no prospective trials have demonstrated the duration of immune checkpoint inhibitor treatments. We are now doing the Japan Clinical Oncology Group 1905 trial, where patients with advanced renal cell carcinoma who have received an immune checkpoint inhibitor for 24 weeks are divided into two groups: those who continue immune checkpoint inhibitor treatment and those who discontinue immune checkpoint inhibitor treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. (Pubmed Central) -  Nov 25, 2021   
    Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u-HCC patients treated with LEN. Our results suggest that LEN is more effective against nonviral u-HCC than against viral u-HCC.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. (Pubmed Central) -  Nov 25, 2021   
    In an HTC/C3 xenograft mouse model, tumor volume was lower in the combined IRAK1/4 Inhibitor I and lenvatinib group compared with that in the vehicle control, IRAK1/4 Inhibitor I, and lenvatinib groups. IRAK1/4 Inhibitor I was identified as a promising compound that enhances the antiproliferative and antitumor effects of lenvatinib in ATC.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. (Pubmed Central) -  Nov 21, 2021   
    Here we examined the effects of ASNase treatment on HCC cells and explored the potential impact of combining ASNase with the tyrosine kinase inhibitor lenvatinib (Len) for HCC treatment...In a xenograft model, Len combined with ASNase significantly attenuated tumor development relative to mice treated with Len or ASNase alone. ASNase-mediated targeting of two amino acids, glutamine and asparagine, which are indispensable for HCC survival, induces oxidative stress and can be a novel cancer treatment option that exerts a synergistic effect when used in combination with Len.
  • ||||||||||  Journal, Checkpoint inhibition:  Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. (Pubmed Central) -  Nov 21, 2021   
    Treatment regimens combining nivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib, and pembrolizumab plus lenvatinib have demonstrated superior overall survival compared with sunitinib in randomized studies...Atezolizumab and pembrolizumab have been approved for the treatment of cisplatin-ineligible patients with metastatic bladder cancer...In patients with metastatic bladder cancer who have progression after immune checkpoint inhibition, there are considerable data supporting the use of enfortumab vedotin. Ongoing studies are evaluating novel combinations of immune checkpoint inhibitors with other agents; thus, the treatment landscape of metastatic bladder and kidney cancer is expected to continue to evolve rapidly.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  The past, present and future of conversion therapy for liver cancer. (Pubmed Central) -  Nov 17, 2021   
    Since conversion study is still in its infancy, there remain controversies in terms of patient selection, choice of treatment method, and postoperative management. In this review, we collect and summarize current evidence and clinical experience of conversion therapy, highlight remaining problems and challenges and provide a foundation for further research and development of HCC treatment in clinical practice.
  • ||||||||||  paclitaxel / Generic mfg., docetaxel / Generic mfg.
    Clinical, Review, Journal:  Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma. (Pubmed Central) -  Nov 17, 2021   
    As cytotoxic agents, S-1, amrubicin, pemetrexed, docetaxel, paclitaxel, and gemcitabine have been reported as prospective phase II studies or retrospective studies...Molecular targeting drugs, such as sunitinib, everolimus, and lenvatinib, also provide clinical effectiveness with tolerability after the failure of platinum-based regimens...However, each study had a small sample size, which may have biased the results of their studies. Further investigation is warranted to elucidate the therapeutic significance of salvage chemotherapy in advanced thymic carcinoma in a large-scale study.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal, Combination therapy:  First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies? (Pubmed Central) -  Nov 17, 2021   
    Several phase III trials show the superiority of combination therapy, dual immunotherapy (ICI-ICI) or ICI plus tyrosine kinase inhibitors (TKI) of the vascular endothelium growth factor (VEGF) over sunitinib monotherapy...A strategy based on the International Metastatic Database Consortium (IMDC) classification is currently recommended with pembrolizumab + axitinib, cabozantinib + nivolumab, and lenvatinib + pembrolizumab (for all patients) or nivolumab + ipilimumab (for patients with intermediate or poor risk), which are the first-line treatment standards of care. However, several issues remain unresolved and require further investigation, such as the PD-L1 status, the relevance of possible options based on the patient's profile, and consideration of second-line and subsequent treatments.
  • ||||||||||  Journal:  Systemic therapy of liver cancer. (Pubmed Central) -  Nov 17, 2021   
    The combination of nivolumab with ipilimumab as an alternative in the treatment of patients treated with sorafenib has inspired various combination studies of immune checkpoint inhibitors...Finally, there is no established adjuvant and neoadjuvant therapy although a few early phase studies show promising results. In this chapter, we summarize current approaches of systemic treatment in patients with liver cancer.